A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

We've heard from green campaign groups, car manufacturers, public chargepoint operators and more. Here's what they've had to ...

Corebridge Financial Inc. decreased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (BMV:SMMT) from Neutral to Buy. Baker Bros. Advisors holds 24,425K shares representing 3.31% ...

Cantor Fitzgerald initiated coverage on Summit Therapeutics, citing shares as 67% undervalued and ivonescimab's strong potential in cancer. Ivonescimab showed significant progression-free survival ...

Shares of NASDAQ SMMT opened at $19.75 on Friday. Summit Therapeutics has a 1-year low of $2.10 and a 1-year high of $33.89. The business’s fifty day moving average price is $20.28 and its two ...

Summit Therapeutics' stock has skyrocketed due to enthusiasm about its experimental cancer drug, ivonescimab. The company plans to report results from a late-stage study of this drug in a few ...

Fintel reports that on March 21, 2025, Cantor Fitzgerald initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Overweight recommendation. Analyst Price Forecast Suggests 76.44% Upside ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...